Funds Holding Novell Inc

 
News Articles for Novell Inc top ^
CAMBRIDGE, Mass., Sept.
Sign-up for Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibodies From AnaptysBio investment picks
SOUTH SAN FRANCISCO, Calif., Sept.
Sign-up for Five Prime Therapeutics Announces Option Exercise by GlaxoSmithKline for a Commercial License to a Novel Muscle Disease Target investment picks
-- T-cell Killing of Human Gastric and Pancreatic Cancer Cell Lines Enhanced With Interferon-α --
Sign-up for Immunomedics Publishes Results on Immunotherapy of Solid Cancers Mediated by a Novel Bispecific Antibody investment picks
Baxter International Inc. (NYSE:BAX) and Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today jointly announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.'' Through the agreement, Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the United States and Taiwan, and Merrimack retains commercialization rights in the United States; the rights in Taiwan are held separately.
Sign-up for Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 investment picks
2014/9/29
At the 60th Annual ASIS International Seminar and Exhibit, the Bruker Detection division introduces RoadRunner™ , an innovative, hand-held explosives and narcotics trace detector with outstanding sensitivity, selectivity, analyte coverage and ease of use.
Sign-up for Bruker Introduces RoadRunner™, a Novel High-Performance Hand-Held Explosives and Narcotics Trace Detector investment picks
Enzo Biochem, Inc. (NYSE:ENZ) today announced that the U.S. Patent and Trademark Office has awarded the Company Patent No.
Sign-up for Enzo Biochem Awarded Patent for Novel Vectors Involving Gene Therapy Treatments for Cancer, Virus Infections and Genetic Diseases investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.
Sign-up for Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia and Hematologic Malignancies investment picks
Aratana to Develop CRTH2 Antagonist for Atopic Dermatitis in Companion Animals KANSAS CITY, Kan.
Sign-up for Aratana Therapeutics and Atopix Complete Global Licensing Agreement for Development and Commercialization of Novel Atopic Dermatitis Program investment picks
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) > Nearly 100,000 people are living with MDS in the US, and both MDS and AML are increasing globally in incidence and prevalence.
Sign-up for Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML investment picks
Comprehensive cryogenic logistics solution integral to the introduction of AmnioClear® LCT therapy LAKE FOREST, Calif.
Sign-up for Cryoport Begins Delivering Novel Cryogenically Preserved Knee OA Treatment to Orthopedists investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G024498-001&sourceType=1 BOTHELL, WA--(Marketwired - October 23, 2014) - Cocrystal Pharma, Inc. (OTCBB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.
Sign-up for Cocrystal Pharma Develops Novel Ebola Screening Technology investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0977272001&sourceType=1 http://media3.marketwire.com/logos/20140729-hmil_logo.png VANCOUVER, BRITISH COLUMBIA --
Sign-up for Highmark Receives Novel Platform Design for Clonal Micropropagation of Cannabis Plants From Dr. Yevtushenko of MJ Bioscience investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Funds Holding Novell Inc
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Funds Holding Novatek Oao Gdr  |  Next: Funds Holding Novo Nordisk A/S